10.15.26 -- Five Raw Material Assumptions That Can Derail Your Outsourced Program

Operational excellence in drug manufacturing relies on a unified culture of integrity and proactive problem-solving. Aligned global teams strengthen the supply chain for reliable patient treatments.

Extracellular Vesicles (EVs) are emerging as promising natural nano-scale platforms for delivering nucleic acids, proteins, and small molecules due to their immune silencing properties.

Embedding manufacturing and regulatory readiness early streamlines development, reduces delays, and supports successful scale-up.

Technology transfer succeeds through trust, shared knowledge, and disciplined execution. See how collaboration, strong documentation, and digital tools reduce risk on the path to GMP.

Explore the challenges when moving a bioconjugate candidate from early development to clinic, along with integrated solutions for navigating this growing area of the biopharmaceutical industry.

Delve into how an optimized, end-to-end development strategy can help sponsors reach key clinical milestones faster and bring potentially life-saving therapies to patients sooner.

Uncover how tighter alignment between vector construction and cell banking improved development efficiency, strengthened risk management, and enhanced early-stage program outcomes.

An expert-led webinar exploring nucleic acid therapeutic modalities, delivery systems, formulation challenges, and real-world case studies shaping drug product development.

What does it take to move a molecule from concept to clinic? It’s often more steps – and more time – than biotechs think.

Assimilate how integrated approaches and process simplification can reduce bottlenecks, improve consistency, and support high-quality manufacturing outcomes across increasingly challenging pipelines.

Purpose‑built for modern injectable drug delivery, we integrate advanced aseptic filling, in‑line quality, and capacity to support complex products.

View how modern cell line engineering boosts speed, stability, and scalability across biologics, with practical insights to cut risk and improve readiness for downstream development.

DELs can screen billions of compounds, but library quality determines meaningful results. See how thoughtful design shapes early decisions that influence which drug candidates move forward.

Discover a practical roadmap for replacing animal tests with advanced molecular methods, as well as how regulatory updates and innovative technologies are shaping a sustainable future.